Please assess the completion status of the following clinical trial:

Trial Title: Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has completed or is about to complete Baxter Clinical Study Protocol No. 160603. Participants who have discontinued rHuPH20 and reverted to intravenous or subcutaneous treatment due to an anti-rHuPH20 antibody also may enroll for long-term safety monitoring.~* Participant/caretaker has reviewed, signed and dated informed consent~* Participant is willing and able to comply with the requirements of the protocol~Exclusion Criteria:~* Participant has a serious medical condition such that the participant's safety or medical care would be impacted by participation in Study 160902~* Participant is scheduled to participate in another non-Baxter clinical study involving an investigational product or investigational device during the course of this study~* If female of childbearing potential, participant is pregnant or has a negative pregnancy test and does not agree to employ adequate birth control measures for the duration of the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SC/IGSC, 10% with rHuPH20 followed by SC of IGSC, 10% (safety) (Type: EXPERIMENTAL): Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of SC of IGSC, 10% only (safety follow-up)
- SC/IGSC, 10% with rHuPH20 followed by IV of IGSC, 10% (safety (Type: EXPERIMENTAL): Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of intravenous (IV) administration of IGSC, 10% only (safety follow-up)
- IV treatment with IGSC, 10% only (Type: EXPERIMENTAL): Partial efficacy (trough levels of immunoglobulin G \[IgG\] only) and safety of intravenous (IV) administration of IGSC, 10% only. This was for participants enrolled in the study who had anti-rHuPH20 andibody titer from study160603

Based on this trial design, predict the completion outcome and termination type (if applicable).